Interferons in the treatment of human cancer

Area of Science:

• Biologic antineoplastic agents
• Cancer therapy
• Immunology

Background:

• Interferons are well-known biologic agents for cancer treatment.
• Clinical application of interferons has faced challenges due to unique therapeutic and toxic effects.
• Understanding interferon mechanisms is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To summarize current Phase I and II trial results for interferons in cancer.
• To establish the clinical potential of interferons.
• To describe maximally tolerated dosages for interferon alpha species.

Main Methods:

• Review of current Phase I and II clinical trial data.
• Analysis of interferon alpha production methods (eukaryotic cells and recombinant DNA technology).
• In vitro and in vivo studies of biologic effects.

Main Results:

• Interferons demonstrate a wide range of biologic effects, including antiviral, antiproliferative, immunologic, and enzymologic functions.
• Both naturally produced and bacterially synthesized interferons exhibit similar effects.
• Maximally tolerated dosages for common interferon alpha species have been determined across various disease states.

Conclusions:

• Interferons hold significant clinical potential in cancer therapy.
• Further research into interferon mechanisms and species-specific activity is needed.
• Future applications may involve combination therapies with other antineoplastic biologics like antibodies or chemotherapy.